Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypes

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  De Ronde, Jorma J ^a   Bonder, Marc Jan ^a   Lips, Esther H ^a   Rodenhuis, Sjoerd ^a   Wessels, Lodewyk F A ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BAYESIAN LEARNING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CLASSIFIER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DECISION TREE; GENE EXPRESSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; PREDICTION; RANK SUM TEST; SCORING SYSTEM; SUPPORT VECTOR MACHINE; VALIDITY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ALGORITHM; BREAST NEOPLASMS; CLASSIFICATION; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; PREDICTIVE VALUE; PROCEDURES; STATISTICAL MODEL; TREATMENT OUTCOME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOGISTIC MODELS; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RNA, MESSENGER; SUPPORT VECTOR MACHINES; TREATMENT OUTCOME;

EID: 84897805862     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088551     Document Type: Article

References (25)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, et al. (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 16: 2672-2685.
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, et al. (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24: 1940-1949.
3. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, et al. (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 17: 460-469.
4. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, et al. (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22: 2284-2293. (Pubitemid 41115384)
5. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, et al. (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer research 64: 8558-8565. (Pubitemid 39552068)
6. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, et al. (2006) Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast cancer research and treatment 95: 229-233.
7. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. International journal of cancer Journal international du cancer 118: 1699-1712.
8. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24: 4236-4244.
9. Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, et al. (2011) Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 117: 3682-3690.
10. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, et al. (2006) Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular cancer therapeutics 5: 2914-2918. (Pubitemid 44849019)
11. Borst P, Wessels L (2010) Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9: 4836-4840.
12. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, et al. (2010) Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 16: 5351-5361.
13. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, et al. (2010) Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast cancer research : BCR 12: R5.
14. Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, et al. (2012) GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer science 103: 913-920.
15. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research 30: 207-210. (Pubitemid 34679544)
16. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 99: 909-917. (Pubitemid 39665934)
17. Allen JD, Wang S, Chen M, Girard L, Minna JD, et al. (2011) Probe mapping across multiple microarray platforms. Briefings in bioinformatics.
18. R Development Core Team (2012) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
19. Romanski P (2009) FSelector: Selecting attributes.
20. Hornik K, Buchta C, Zeileis A (2009) Open-Source Machine Learning: R meets Weka. Computational Statistics 24(2): 225-232.
21. Witten IH, Frank E, Hall MA (2011) Data Mining: Practical Machine Learning Tools and Techniques: Morgan Kaufmann.
22. Wessels LF, Reinders MJ, Hart AA, Veenman CJ, Dai H, et al. (2005) A protocol for building and evaluating predictors of disease state based on microarray data. Bioinformatics 21: 3755-3762. (Pubitemid 41535524)
23. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27: 1160-1167.
24. Horiguchi J, Oyama T, Takata D, Rokutanda N, Nagaoka R, et al. (2011) Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Anticancer Res 31: 3041-3046.
25. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, et al. (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 20: 485-490.